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SUMMARY
The vascular endothelium operates in a highly po-
larized environment, but to date there has been
little exploration of apicobasal polarization of its
signaling. We show that VEGF-A, histamine, IGFBP3,
and LPA trigger unequal endothelial responses when
acting from the circulation or the parenchymal side at
blood-neural barriers. For VEGF-A, highly polarized
receptor distribution contributed to distinct signaling
patterns: VEGFR2, which was found to be predomi-
nantly abluminal, mediated increased permeability
via p38; in contrast, luminal VEGFR1 led to Akt acti-
vation and facilitated cytoprotection. Importantly,
such differential apicobasal signaling and VEGFR
distribution were found in the microvasculature of
brain and retina but not lung, indicating that endothe-
lial cells at blood-neural barriers possess specialized
signaling compartments that assign different func-
tions depending on whether an agonist is tissue or
blood borne.
INTRODUCTION
Endothelial polarity is assumed to be mechanistically similar to
that of epithelial cells, where it is well studied. Undoubtedly,
the morphological and molecular organization of the vascular
endothelial cells (ECs) at any of the diverse blood-tissue inter-
phases must reflect the highly polarized environment in which
they operate. For instance, vascular lumen formation is entirely
dependent on segregation of apical and basal membrane com-
partments and subsequent EC polarization (Lizama and Zovein,
2013). A huge body of work has also demonstrated that at
vascular blood-brain or blood-retinal barriers, neuronal homeo-
stasis is maintained by highly polarized localization of trans-
porters and channels, which regulate the directional movement
of ions, drugs, metabolites, and toxins (Abbott et al., 2010).
Thus, it is assumed that, in their naturally highly polarized envi-
ronment, ECs have adopted differential apicobasal signaling.
However, experimental proof of such polarized signaling pro-
cesses is still missing.
Vascular endothelial growth factor (VEGF) family members,
and in particular its most studied representative VEGF-A, are
central to the creation of new blood vessels during normal devel-
opment and growth but also in pathological situations such as
tumorigenesis and ocular neovascular disease (Koch et al.,
2011; Takahashi and Shibuya, 2005). Besides its angiogenic
role, VEGF-A has additional effects on the vascular endothelium.
It was originally discovered for its ability to trigger vascular
permeability, and this permeability-enhancing property of
VEGF-A is linked to interstitial fluid accumulation in tumors and
psoriatic lesions, aswell as tissue edema and concomitant vision
loss in neovascular eye disease (Ferrara et al., 2007). VEGF-A
also has beneficial roles in the systemic vasculature, regulating
normal vascular tone and acting as a trophic factor for the
vascular endothelium (Maharaj and D’Amore, 2007).
VEGF-Amediates its diverse functions through the use of mul-
tiple receptors, mainly the receptor tyrosine kinases VEGFR1
(Flt-1) and VEGFR2 (Flk-1/KDR) (Koch et al., 2011). The most
common splice isoform VEGF-A(165), subject of the present
study, additionally interacts with neuropilin 1 and various cell-
surface heparan sulfate proteoglycans to modulate the intra-
cellular response. VEGF-A belongs to a family of growth factors
with five genes encoding VEGF-A, -B, -C, and -D and placental
growth factors (PlGFs), each binding VEGFRswith different affin-
ities. For instance, PlGF-1 and the viral gene product VEGF-E
specifically bind and activate VEGFR1 and VEGFR2, respec-
tively (Takahashi and Shibuya, 2005).
VEGF-A triggers a plethora of intracellular signaling steps in
ECs (Koch et al., 2011). Standout mediators associated with
the VEGF-A-induced endothelial permeability response are the
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mitogen-activated protein kinases Erk and p38, phospholipases,
protein kinase C, phosphatidylinositol 3-kinase (PI3K)-activated
Akt, and endothelial nitric oxide synthase (eNOS) (Weis and
Cheresh, 2005). However, given the complexity of VEGF-A
signaling and the permeability response, as well as the morpho-
logical and cytological differences of various endothelia, it is not
surprising that these signaling components remain under intense
scrutiny, in particular with respect to their specific role in partic-
ular experimental models and their interaction with each other in
controlling various effector mechanisms.
Because of VEGF-A’s central role in the regulation of endothe-
lial functions in health and disease, anti-VEGFs have become
irreplaceable tools in treating pathological angiogenesis and
permeability (Ferrara et al., 2007). However, systemic anti-
VEGF-A therapies are associated with endothelial dysfunction
leading to bleeding, inflammation, hypertension, proteinuria,
and even lethality (Chen and Cleck, 2009). Consistent with these
observations in patients, animal models demonstrate that VEGF-
A is constitutively required to maintain vascular tone and
vascular EC survival and that reductions in plasma VEGF-A
levels cause vascular attrition and functional abnormalities (Su-
gimoto et al., 2003).
We therefore hypothesized that circulating and tissue-pro-
duced VEGF-A induce distinct responses in ECs. In light of the
central role of VEGF-A as a permeability-inducing factor in brain
(Merrill and Oldfield, 2005; Argaw et al., 2012) and eye pathol-
ogies (Miller et al., 2013), our study focused on vascular ECs at
blood-neural barriers and on acute endothelial permeability (as
opposed to chronic interstitial fluid accumulation during inflam-
mation, cancer, and wound healing, which may involve cells
other than ECs) (Nagy et al., 2008). Our study is also restricted
to the in vitro and in vivo analysis of the microvasculature as
opposed to the macrovasculature, because this is where physi-
ological and pathological vascular permeability occurs. Here we
report that VEGF-A induces unequal responses depending on
whether it acts on the luminal or abluminal side of neural micro-
vascular ECs (MVECs). Mechanistically, this differential EC
response is predicated on polarized VEGFR expression and
distinct downstream signaling.
RESULTS
Using contrast-enhanced magnetic resonance imaging (MRI) in
the mouse, we determined tissue extravasation of intravenous
(i.v.) injected gadolinium (gadolinium diethylenetriamine penta-
acetic acid [Gd-DTPA], 742 Da). Basal leakage of Gd-DTPA
was significantly higher in peripheral tissues such as the lung
than the brain or the eye, reflecting the significant difference in
baseline permeability between neural and nonneural vascular
beds. Intravenous injection of VEGF-A (3 mg/mouse) significantly
enhanced leakage of Gd-DTPA into lungs within 10 min (Fig-
ure 1A), in agreement with previous reports of VEGF-A-induced
permeability in nonneural vasculature, such as that of the tra-
chea or the mesentery (Sun et al., 2012; Bates and Curry,
1996). Significantly, no leakage was observed in the brain or
the eye over a 30 min observation period. However, when
VEGF-A was directly injected into the brain cortex or the vitreous
of the eye, rapid and significant accumulation of Gd-DTPA in the
vicinity of the injection site was observed (Figures 1B and 1C),
indicating that only tissue-borne but not circulating VEGF-A
induced vascular hyperpermeability in the neural tissues.
This was further studied in single pial microvessels, which
exhibit barrier properties closely resembling those found at the
intact blood-brain barrier (BBB) and allow permeability measure-
ments that are tightly controlled with respect to kinetics and
dose (Butt et al., 1990; Easton et al., 1997). Increasing VEGF-A
levels up to 2 mg/ml within the lumen of tight pial microvessels
did not affect baseline permeability (Figures 1D and 1F), even
when bradykinin triggered strong vascular permeability (Figures
1E and 1F). In contrast, exposure to VEGF-A from the tissue side
led to a rapid increase of permeability (Figures 1G and 1H), which
was maximal at a concentration of ca. 50 ng/ml. Taken together,
these data demonstrated that cerebral microvascular per-
meability is strongly induced by VEGF-A, albeit only when pre-
sented to the abluminal face of microvessels.
The microvasculature in the brain and retina constitutes a
network of ECs tightly interacting with mural cells such as peri-
cytes and glial cells including astrocytes andMu¨ller cells (Abbott
et al., 2010). Because microvascular permeability operates pri-
marily on the level of endothelium, we tested whether the ECs
themselves responded to VEGF in a polarized fashion. For this,
we used highly purified nonpassaged, primary MVECs isolated
from brain or retina, which were characterized by preservation
of interendothelial junctions, apicobasal polarity, and very
good in vitro barrier properties (Figure S1 available online).
Macromolecular apical-to-basal flux was enhanced nearly 2-
fold when 50 ng/ml VEGF-A was added to the basal side of rat
brainMVECmonolayers, whereas doses of up to 1 mg/ml applied
to the apical side did not change flux (Figures 2A–2D). A similar,
polarized response to VEGF-A was also observed in cultures of
murine brain (data not shown) and rat or porcine retinal MVECs
(Figures 2E and 2F), suggesting that functional polarity operates
at all vascular blood-brain and -retinal barriers and across spe-
cies. Importantly, both barrier properties and the sided response
to VEGF-A were lost following repeated subculturing of MVECs
(Figures S1D–S1F), offering a plausible explanation as to why
this phenomenon has not yet been universally observed.
VEGF-A also induced changes in transendothelial electrical
resistance (TEER) and significant reduction in junctional claudin
5 (Cldn5) (Figures 2G and 2H), a reliable molecular indicator of
MVEC barrier and BBB integrity (Nitta et al., 2003), indicating
that paracellular rather than transcellular permeability was oper-
ational (Steed et al., 2010). VEGF-A provoked flux and TEER
changes within minutes (Figures 2B and 2I), thus resembling
the acute response observed in vivo. A sided permeability
response similar to that with VEGF-Awas also observedwith his-
tamine and insulin-like growth factor-binding protein 3 (IGFBP3)
(Figure 2J), whereas opposite responsiveness was observed
with lysophosphatidic acid (LPA). Thrombin and bradykinin
induced significant flux in brain MVECs but without predilection
for either endothelial face. Significantly, the sided response to
histamine and LPA was consistent with previous results from
pial microvessels in vivo (Sarker et al., 1998, 2010).
One explanation for the polarized responses to VEGF-A is that
distinct signaling pathways, and in particular different VEGF-A
receptors, operate on the apical and basal sides of brain or
retinal MVECs. To test this hypothesis, we studied the distribu-
tion of VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1) (Koch et al.,
Developmental Cell
VEGF-Induced Permeability at Blood-Neural Barriers
542 Developmental Cell 30, 541–552, September 8, 2014 ª2014 The Authors
2550
A Transverse thorax (Lungs) Coronal head (Brain) Coronal head (Eyes)
0
50
100
150
200
Saline VEGF-A
P
ix
e
l 
In
te
n
s
it
y
(a
.u
.)
0
25
50
75
100
Saline VEGF-A
P
ix
e
l 
In
te
n
s
it
y
(a
.u
.)
V
E
G
F
-A
  
 i
.v
.
S
a
li
n
e
i.
v
.
C
0
50
100
150
Saline VEGF-A
%
in
c
re
a
s
e
*
B
0
50
100
150
Saline VEGF-A
%
in
c
re
a
s
e
*
H
0
0.5
1
1.5
2
2.5
12.5
P
e
rm
e
a
b
il
it
y
C
h
a
n
g
e
(1
0
-6
c
m
. s
-1
)
VEGF-A (ng/mL)
25 50
**
100
**
F
VEGF-A (ng/mL)
P
e
rm
e
a
b
il
it
y
C
h
a
n
g
e
(1
0
-6
c
m
.s
-1
)
BK
**
0
0.5
1
1.5
2
-0.5
-1
2000100
-1.5
E
0
50
100
150
200
P
ix
e
l 
In
te
n
s
it
y
 (
a
.u
.)
0 20 40 60
Time (s)
Saline; P= 0.6
VEGF-A; P= 5.6
G
0
50
100
150
200
P
ix
e
l 
In
te
n
s
it
y
 (
a
.u
.)
0 20 40 60
Time (s)
BK; P= 5.1
0
50
100
150
200
P
ix
e
l 
In
te
n
s
it
y
 (
a
.u
.)
0 20 40 60
Time (s)
Saline; P= 1.5
D
S
a
lin
e
0
50
100
150
200
P
ix
e
l 
In
te
n
s
it
y
 (
a
.u
.)
0 20 40 60
Time (s)
Saline; P= 1.7
0
50
100
150
200
P
ix
e
l 
In
te
n
s
it
y
 (
a
.u
.)
0 20 40 60
Time (s)
VEGF-A; P= 1.7
V
E
G
F
-A
S
a
lin
e
B
K
S
a
lin
e
V
E
G
F
-A
2.5
3
0
50
100
150
200
Saline VEGF-A
P
ix
e
l 
In
te
n
s
it
y
(a
.u
.)
*
Figure 1. Abluminal but Not Luminal VEGF-A Induces Permeability In Vivo
(A–C) T-1-weighted MRI in mice showed increased extravasation of Gd-DTPA (742 Da) in the lungs (circled) but not the brain or eyes in response to i.v. VEGF-A
(3 mg/animal) (A). In contrast, direct injection of VEGF-A (ca. 8 ng) into the brain cortex (B; arrows indicate injection sites) or the vitreous of the eye (C) led to
increased extravasation. Shown are representative contrast-enhanced and 16-color pseudocolored images taken 8 min after VEGF-A injection, with densito-
metric quantification of each experimental group shown beneath. a.u., arbitrary units.
(D and E) Time-dependent recording of sulforhodamine B (580 Da) loss from single occluded rat pial microvessels in vivo showed no change of permeability in
response to an intracarotid (i.e., luminal) bolus injection of VEGF-A (100 ng/ml) (D). In contrast, luminal bradykinin (BK) at 10 mM induced a rapid loss of dye (E).
Shown are micrographs of pseudocolored microvessels at indicated times (min:s) after either saline or VEGF-A or bradykinin injection. The dotted outline in the
first image in each series indicates the position of the occluding probe. Densitometric fluorescence intensities were plotted against time, and permeability values
P (106 cm/s) were calculated by fitting data to the equation Ct = C0 e
kt, where k = 4P/d and d is the diameter of the vessel.
(F) Mean permeability changes determined as described in (D) and (E) in response to either 10 mM bradykinin or 100 or 2,000 ng/ml VEGF-A.
(G) Application of VEGF-A (100 ng/ml) to the abluminal, extravascular space of single pial microvessels in vivo produced a strong increase of permeability to
sulforhodamine B (580 Da). The scale bar represents 50 mm.
(H) Mean permeability changes in response to increasing concentration of VEGF-A.
Data are means ± SEM of at least three independent experiments. **p < 0.01, ***p < 0.001 [Student’s t test (A–C) and ANOVA and Dunnett’s post hoc test (F
and H)].
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Figure 2. Basal, but Not Apical, VEGF-A Induces Permeability in Cultured Cerebral or Retinal MVECs
(A–C) Rat cerebral MVECs were grown on permeable Transwell inserts until they reached a TEER of greater than 200 U/cm2. FITC dextran (4 kDa) was added to
the apical chamber and flux was measured as the time-dependent accumulation of fluorescence in the basal chamber. VEGF-A (50 ng/ml) addition to the apical
side of the cells (at time 0) did not change flux rates (A). In contrast, a rapid change in flux was observed when it was added to the basal side of the cells (B). Dotted
lines are linear regressions of data points before and after the addition of VEGF-A. Mean fold changes of flux following apical or basal application are shown in (C).
(D) Flux was measured as in (A)–(C) in the presence of apical VEGF-A at the indicated concentrations, none of which led to significant flux changes.
(E and F) Basal but not apical VEGF-A (50 ng/ml) also induced significant 4 kDa FITC dextran flux changes in postconfluent rat (E) or porcine (F) retinal MVECs.
(legend continued on next page)
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2011). Cryoimmunogold electron microscopy (EM) showed that
ca. 75% of VEGFR1 was found apically in rat brain MVECs,
whereas ca. 70% of VEGFR2 was found at basal membranes
(Figure 3A; Table S1). Analysis by domain-specific biotinylation
(Figure 3C) or analysis by confocal microscopy (Figures S2A
and S2B) confirmed this highly polarized distribution pattern.
Importantly, distribution of VEGFR1 and VEGFR2 was also pre-
dominantly luminal and abluminal, respectively, in the microvas-
cular endothelium of the mouse hippocampus (Figure 3B; Table
S1). VEGF receptor distribution was also interrogated in vivo: the
luminal side of the mouse vasculature was exposed for 5 min to
anti-VEGFR1 or -R2 antibodies by cardiac injection. Following
perfusion, VEGFR antibody binding was studied by fluorescent
secondary antibody labeling of retinae and lungs (Figure 3D; Fig-
ure S2C). VEGFR1 antibodies bound to retinal and lung micro-
vessels, whereas VEGFR2 antibodies strongly labeled lung but
not retinal microvessels. In contrast, when the same antibodies
were applied abluminally for 5 min to unfixed and nonpermeabi-
lized retinae, VEGFR2 but not -R1 was detectable in retinal ves-
sels. In addition, both antibodies strongly reactedwith other cells
in the retinal ganglion cell layer, consistent with the reported
expression of VEGF receptors in ganglion and Mu¨ller cells
(Saint-Geniez et al., 2008; Foxton et al., 2013). Taken together,
the majority of VEGFR1 and -R2 was found to be inversely
located to the luminal and abluminal sides, respectively, of
MVECs in the brain and the retina but not the lung.
These data strongly suggested that different downstream sig-
nals operate in response to apical or basal VEGF. Indeed, we
found that the time-dependent activation of p38 and Akt was
significantly different following apical or basal exposure of brain
MVECs to VEGF-A. Phosphorylation of p38, increasing over
time, was observed in response to basal but not apical VEGF-
A (Figure 4A). In contrast, Akt activation was only seen following
apical exposure to VEGF-A. Apical but not basal exposure to
PlGF-1, which selectively binds to VEGFR1 (Takahashi and Shi-
buya, 2005), also induced Akt phosphorylation, with a peak at ca.
30 min (Figure 4B). In contrast, stimulation with the VEGFR2-se-
lective ligand VEGF-E (Takahashi and Shibuya, 2005) did not
lead to Akt activation from any side of the ECs. Instead, strong
phosphorylation of p38 was observed within 5 min of basal but
not apical exposure.
The hallmarks of this differential p38 and Akt activation pattern
could be recapitulated by VEGF treatment in vivo. In rats, intrave-
nous injection of neither VEGF-A, PlGF-1, nor VEGF-E (120 mg/kg)
led to any activation of p38 in pial microvessels (Figure 4C).
Nevertheless, in alveolar lung vessels of the same animals, p38
was strongly and rapidly activated in response to i.v. VEGF-A or
VEGF-E but not PlGF-1 (Figure S3). In pial microvessels, VEGF-
A and VEGF-E led to rapid p38 activation, but only when growth
factors were administered from the tissue side through a cranial
window (Figure 4C). We also attempted to study Akt activation
in a similar manner. However, none of six different commercial
anti-phospho-Akt antibodies produced significantly altered stain-
ing patterns in brain, lung, or retinal tissues of rats treated with
time courses of luminal or abluminal VEGFsor indeed insulin, sug-
gesting that reliable phospho-Akt detection was not possible by
immunohistochemistry (data not shown). We therefore opted to
study Akt activation in whole-cell lysates of retinal tissue. Intrave-
nous injection of VEGF-A or PlGF-1 but not VEGF-E led to strong
Akt activation after 25 min (Figure 4D). Some weak activation of
p38 was also observed under these conditions. Direct injection
of VEGFs into the retina (i.e., abluminal application) did not lead
to any significant Akt phosphorylation. Taken together, these
data demonstrated that in cerebral or retinal MVECs, rapid p38
activation occurred downstream of abluminal VEGFR2. In con-
trast, Akt activation occurred more slowly and downstream of
luminal VEGFR1.
This polarized signaling pattern was not only in full agreement
with the VEGFR1 and -R2 localization described in Figure 3 but
also with the endothelial permeability response. Enhanced
macromolecular flux across brain MVECs was seen following
basal (but not apical) VEGF-E stimulation, whereas PlGF-1 had
no effect on barrier function, neither in vitro nor in vivo (Figures
5A and 5B). Furthermore, we found that SB202190, but not wort-
mannin or LY294002, which inhibited VEGF-induced p38 or Akt
activation, respectively (Figures S4A and S4B), abrogated
VEGF-induced hyperpermeability in vitro and in vivo (Figures
5C and 5D; Figure S4C). Taken together, this clearly indicated
that the permeability response to VEGF at blood-neural barriers
is mediated by abluminal VEGFR2. In agreement, the VEGFR2
inhibitor SU1498 completely abolished VEGF-A-induced flux in
brain MVECs (Figure S4C).
Abundant data suggest that systemic (hence, luminal) VEGF-A
is a trophic factor for the vasculature (Maharaj and D’Amore,
2007; Gerber et al., 1998). In light of the specific activation of
Akt following luminal VEGFR1 stimulation, we investigated a po-
tential role in endothelial cytoprotection. Rat brain MVECs were
stimulated with themicrobial alkaloid staurosporine, widely used
to induce apoptosis inmost cell types, including ECs (Kabir et al.,
2002). Apoptosis, measured as an increase in caspase 3/7 activ-
ity, was significantly reduced by apical VEGF-A or PlGF-1 but not
VEGF-E (Figure 6A). This VEGF-mediated cytoprotection was
sensitive to wortmannin but not to SB202190 (Figure 6B). To
this end, a potential role of VEGF in cytoprotection of retinal
ECs could not be interrogated in vivo, because staurosporine
was ineffective in inducing EC death. Staurosporine was applied
(G) Postconfluent rat cerebral MVECs grown on permeable Transwell inserts were subjected either apically or basally to 50 ng/ml VEGF-A, and time-dependent
changes in electrical resistance were monitored by impedance spectroscopy.
(H) Changes in the distribution of Cldn5 and VE-cadherin in response to either apical or basal VEGF-A (50 ng/ml, 1 hr) were analyzed by confocal microscopy in
postconfluent rat cerebral MVECs. Shown are representative projections spanning the entire thickness of the monolayers. The scale bar represents 10 mm.
(I) As in (G), except that direct TEER changes were measured every ca. 30 s using chopstick electrodes. VEGF-A (50 ng/ml) was added to the basal side at time 0.
(J) Transendothelial flux was measured in postconfluent primary rat brain MVECs in response to apical or basal histamine (100 mM; HIS), IGFBP3 (50 ng/ml), LPA
(10 mM), thrombin (1 U/ml; THR), or bradykinin (10 mM; BK).
Data aremeans ± SEMof at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant [Student’s t test (C, E, F, and J), ANOVA (D),
or two-factor analysis of variance (location of VEGF application by time) with one repeatedmeasure (time) (G)]. Note that in (J), only p values of apical versus basal
treatments are shown.
See also Figure S1.
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Figure 3. Differential VEGF Receptor Localization in Microvascular ECs in Brain and Retina
(A and B) Cryoimmunogold EM analysis of VEGFR1 and -R2 in primary rat brain MVECs (A) or mouse hippocampal microvessels (B) showed predominant apical/
luminal (black) and basal/abluminal (brown) localization, respectively. Mean distribution of each VEGF receptor (±SEM) was determined by quantifying gold
(legend continued on next page)
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to mouse or rat retinae both intravitreally and through the carotid
artery at up to 40 mM for up to 12 hr. This treatment induced se-
vere retinal ganglion cell death but did not affect ECs at all (data
not shown). Even when additionally circulating VEGF-A was
reduced by coadministration of anti-VEGF antibodies, we could
not measure any annexin V binding or activated caspase 3 stain-
ing in retinal ECs (data not shown). Thus, VEGF mediates a cyto-
protective response in rat brain MVECs in culture, with signaling
via VEGFR1 and Akt but not VEGFR2 and p38. In the neuronal
vasculature in vivo, VEGF-A is likely to be only part of a complex
network of environmental cytoprotective factors (see below).
DISCUSSION
The vascular endothelium operates in a highly polarized environ-
ment, but to date there has been little exploration of polarized
endothelial signaling. Here we demonstrate that luminal and
abluminal EC surfaces of blood-neural barriers display different
functionality during acute responses to VEGF-A as well as hista-
mine, IGFBP3, and LPA. In particular, we found that cerebral and
retinal vascular permeability was completely refractory to circu-
lating VEGF-A. In contrast, the lung vasculature responded to
circulating VEGF-A and VEGF-E with enhanced permeability
and p38 activation. Because mesenteric and tracheal microves-
sels also induce permeability in response to luminal VEGF-A
(Sun et al., 2012; Bates and Curry, 1996), our findings appear
to have revealed a clear specialization of the blood-neural barrier
endothelium. Importantly, our data are consistent with VEGF-A’s
well-established role as a paracrine factor produced by hypoxic/
ischemic tissue (see also Figure 7), for instance by astrocytes
during central nervous system inflammatory disease (Argaw
et al., 2012) and pathological retinal angiogenesis (Weidemann
et al., 2010) or by Mu¨ller cells during diabetes-induced retinal
ischemia (Wang et al., 2010). The sided responsiveness of these
MVECs to VEGF-A was attributable to highly polarized expres-
sion of the receptor tyrosine kinases VEGFR1 and -R2 and
distinct downstream activation of key signaling pathways.
VEGF receptor localization was polarized strongly but not in an
absolute manner. Nevertheless, the permeability response and
the signaling response of the microvascular endothelium was
completely polarized. General computational modeling of
VEGF receptor surface distribution (Mac Gabhann and Popel,
2007) suggests that the distribution pattern we observed in cere-
bral and retinal ECs would result in luminal VEGFR1 homodimers
and some VEGFR1-R2 heterodimers but no VEGFR2 homo-
dimers. In contrast, basal membranes would be rich in VEGFR2
homodimers (and heterodimers) but devoid of VEGFR1 homo-
dimers (see also Figure 7). We speculate that this absence of
VEGFR2 and VEGFR1 homodimers on the luminal and abluminal
surface of neural ECs produces exclusivity with regard to loca-
tion and receptor specificity of ligands. In particular, in this
model, p38 and Akt activation would be exclusively associated
with VEGFR2 and VEGFR1 homodimer signaling, respectively.
Indeed, Cudmore et al. have recently shown that VEGFR2 yields
different cellular responses depending on whether it is engaged
in homo- or heterodimers (Cudmore et al., 2012). In addition, co-
receptors such as neuropilin 1 may also play a role (Becker et al.,
2005). Future experiments using heterodimeric ligands such as
PlGF-1-VEGF-E (Cudmore et al., 2012) could establish the role
of VEGFR1-R2 heterodimers in the differential signaling res-
ponse of brain and retinal ECs.
In line with generally accepted views (Takahashi and Shibuya,
2005; Issbru¨cker et al., 2003), VEGFR2 and p38 activities were
associated with the permeability-enhancing response of VEGF-
A. In contrast, and judging by activation profiles and PI3K inhibi-
tion, we did not detect any involvement of Akt in VEGF-induced
permeability in the brain. Indeed, conflicting results have been
reported regarding a direct role of Akt in vascular permeability
(Six et al., 2002; Chen et al., 2005), and its involvement has
frequently been inferred by the need for activation of the Akt sub-
strate eNOSduring VEGF-mediated permeability (Takahashi and
Shibuya, 2005). However, in cerebral MVECs, eNOS activation
can also occur in an Akt-independent manner, in particular dur-
ing inflammation (Martinelli et al., 2009). We did not find a role for
VEGFR1 inmediating acute brain permeability either. This recep-
tor has been proposed tomediate permeability in a more chronic
and auxiliary way (Takahashi and Shibuya, 2005; Koch et al.,
2011), which would not likely be captured in our model systems.
In addition, a direct role of VEGFR1 in permeability may be
restricted to nonneural vascular beds (Odorisio et al., 2002).
Instead, and in line with it activating Akt, a kinase regarded as
synonymous to the cell-survival response (Datta et al., 1999), we
found a clear role of VEGFR1 in cytoprotection. A cytoprotective
role of VEGF-A for ECs is well documented (Gerber et al., 1999),
with most mechanistic evidence derived from in vitro culture
models. For instance, in umbilical vein ECs, the main VEGF re-
ceptor mediating survival appears to be VEGFR2 (Gerber et al.,
1998; dela Paz et al., 2012), whereas in microvascular retinal or
dermal ECs there is evidence that VEGFR1 is involved (Cai
et al., 2003; Zhang et al., 2010), suggesting that receptor usage
may differ between vascular beds. Whereas we were able to find
clear experimental support for VEGFR2-mediated permeability
in vitro and in vivo, the cytoprotective function of VEGFR1 has
so far only been observed in cultured cerebral MVECs. Our fail-
ure to inducemeasurable apoptosis in retinal ECs in vivo through
staurosporine and VEGF-A withdrawal suggests that additional
particles located within ca. 20 nm of the plasma membrane (as indicated by arrowheads) in five independent sections, each comprising at least 10 mm of
continuous plasma membrane. The scale bars represent 100 nm.
(C) VEGF receptor distribution was also analyzed in postconfluent rat cerebral MVECs by biotinylation of either the apical or, in the presence of EDTA, the apical
and basal membranes (ap+bl). Biotinylated proteins were isolated and analyzed bywestern blot. Shown are representative immunoblots of VEGFR1 and VEGFR2
and quantitative distribution analysis from three experiments (means ± SEM).
(D) VEGFR1 but not -R2 antibodies bound to the retinal vasculature of mice within 5 min of luminal delivery through cardiac injection. However, in the same
animals, both VEGFR1 and -R2 antibodies were found bound to alveolar microvessels in the lung. Inversely, when unfixed, nonpermeabilized retinae were
incubated with VEGFR antibodies (abluminal), only VEGFR2 was found to stain microvessels significantly. All whole mounts and sections were counterstained
with the vessel marker isolectin B4 and analyzed by confocal microcopy. Shown are optical sections of ca. 8 mm thickness of the retinal ganglion cell layer or the
center of the lung. The scale bars represent 20 mm.
See also Figure S2 and Table S1.
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Figure 4. Differential VEGF Receptor Signaling in Brain MVECs and Neural Microvessels
(A) Basal but not apical VEGF-A (50 ng/ml) induced significant activation of p38 but not Akt in postconfluent primary rat brain MVECs. In contrast, Akt but not p38
was activated in response to apical VEGF-A. At the indicated times of VEGF-A stimulation, whole-cell lysates were prepared and levels of phosphorylated p38
(pT180/Y182) and Akt (pS473) were determined by western blotting. Shown are representative blots and normalized densitometric quantifications.
(B) Kinase response to PlGF-1 or VEGF-E analyzed as in (A). p38 was activated within 5 min of basal but not apical VEGF-E (50 ng/ml) treatment, whereas slower
Akt activation was seen in response to apical but not basal PlGF-1 (50 ng/ml).
(C) Intravenously injected VEGF-A, PlGF-1, or VEGF-E (at 120 mg/kg) (luminal) did not induce activation of p38 in the pial vasculature of P23 rats. When applied
abluminally to the pial microvasculature (at 100 ng/ml) (abluminal), VEGF-A and VEGF-E but not PlGF-1 led to rapid activation of p38. Pial tissues were fixedwithin
5min of treatment and then stained for phosphorylated p38 (pT180/Y182). All sections were counterstained with the vessel marker isolectin B4 (IB4) and analyzed
by confocal microscopy. Shown are projections spanning a thickness of ca. 11 mm. The scale bar represents 20 mm.
(D) VEGF-A, PlGF-1, or VEGF-E was either injected into the tail vein of P23 rats (at 120 mg/kg) or into the vitreous (i.o.; 100 ng/eye). After ca. 20 min, retinae were
isolated and subjected to quantitative immunoblot analysis as described for (A) and (B). Akt was robustly activated in response to i.v. but not i.o. injected VEGF-A
and PlGF-1. p38 was weakly activated as well. VEGF-E did not induce any significant effects.
Shown are means ± SEM from at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 [ANOVA and Dunnett’s post hoc test (A, B, and D)]. See
also Figure S3.
Developmental Cell
VEGF-Induced Permeability at Blood-Neural Barriers
548 Developmental Cell 30, 541–552, September 8, 2014 ª2014 The Authors
growth (Walshe et al., 2009) or environmental factors such as
flow (dela Paz et al., 2012; Dimmeler and Zeiher, 2000) contribute
to EC survival, in particular in the brain and the eye (Ueno et al.,
2008). Numerous experiments also show that the apoptotic
response of ECs in vivo is relatively slow and only measurable af-
ter several days (Meeson et al., 1999; Sugimoto et al., 2003), and
thus not within the time frame of our current experimental setup.
Overall, our findings are compatible with previous reports but
clearly identify a high degree of specialization of VEGF signal
transduction at blood-neural barriers. Specification of VEGF-A
action occurs through many mechanisms, including the creation
of functionally distinct protein isoforms, the presence of multiple
surface, soluble, and coreceptors, and the sequestration of the
ligand in the extracellular matrix (Koch et al., 2011). In addition,
our data suggest that ECs are able to control the response to
VEGF-A through compartmentalizing cellular signaling, and pro-
vide an intriguing explanation of how blood-neural barriers can
be maintained despite constant exposure to circulating VEGF-
A. Finally, the ability to map the vascular permeability response
to a distinct topological signaling domain within the EC provides
a new opportunity to specifically target pathological aspects of
VEGF-A while preserving essential cardiovascular functions.
EXPERIMENTAL PROCEDURES
Animals
Wistar and Lewis rats and C75BL/6J mice were purchased from Harlan Labo-
ratories. All procedures were performed in accordance with UK and Ireland
Animal Welfare Acts and with the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision
Research and the Animal Welfare and the Ethical Review Bodies of the UCL
Institute of Ophthalmology, King’s College London, and Trinity College Dublin.
Recombinant VEGFs
Recombinant rat VEGF-A(165) was purchased from R&D Systems, VEGF-E
was from Cell Sciences (or a kind gift from Kurt Ballmer-Hofer), and human
PlGF-1 was from PeproTech.
Magnetic Resonance Imaging
Vascular permeability in lungs, brain, and eyes was assessed in vivo via MRI
(Campbell et al., 2012) using a dedicated small rodent 7 T MRI system
(http://www.tcd.ie/neuroscience/infrastructure/neuroimaging/index.
php#7tesla).
In Vivo Permeability Measurements
The pial microvasculature ofWistar rats (age 25–30 days) was exposed and the
permeability wasmeasured as described previously (Easton and Fraser, 1994;
Easton et al., 1997).
MVEC Isolation
Microvessels were isolated from rat or mouse cortical gray matter or rat or
porcine retinae by collagenase dispase digestion and BSA and Percoll density
gradient centrifugation (Abbott et al., 1992). Purified vessels were seeded onto
collagen IV/fibronectin-coated tissue-culture ware or Costar Transwells (3460)
at high density (vessels from 6 rat brains or 12 retinae per 40 cm2 or 3 cm2,
respectively). Cells were grown in EGM2-MV (Lonza) (with 5 mg/ml puromycin
during the first 5 days; Perrie`re et al., 2007) for 2–3 weeks until their TEER
plateaued at values above 200 U/cm2.
Immunocytochemistry
MVECs were grown on collagen IV/fibronectin-coated tissue-culture ware or
12 mm Costar Transwell filters. Cells were fixed using 3.7% formaldehyde
and extracted in acetone (20C). Alternatively, they were fixed and permea-
bilized simultaneously in 80%MeOH, 3.2% formaldehyde, 50 mMHEPES (pH
7.4) (Martins et al., 2013). Staining was performed as previously described
(Turowski et al., 2004) using antibodies against von Willebrand factor (Dako),
VE-cadherin (Martins et al., 2013), occludin and Cldn5 (Invitrogen), VEGFR1
(sc-31173; Santa Cruz Biotechnology), VEGFR2 (ab11939; Abcam), and
P-glycoprotein (clone C219).
Immunogold Electron Microscopy
Paraformaldehyde (PFA)-fixed brains from 10-month-old mice were isolated
and 50 mm hippocampal slices were dissected out and postfixed for 2 hr in
4% PFA. MVECs on Transwell filter inserts were fixed in 4% PFA and 0.1%
glutaraldehyde. Fixed samples were processed as previously described
(Eden et al., 2010). Briefly, samples were embedded in 12% gelatin in 0.1 M
phosphate buffer (pH 7.4). After infusion with 2.3 M sucrose at 4C overnight,
80 nm sections were cut at 120C using a cryoultramicrotome and collected
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Figure 5. VEGFR2 and p38 Mediate the Brain
Microvascular Permeability Response
(A) Transendothelial flux of 4 kDa dextran
across confluent primary rat brain MVECs was
increased in response to basal but not apical VEGF-E
(50 ng/ml). PlGF-1 (50 ng/ml) did not affect flux.
(B) Application of VEGF-E but not PlGF-1 to
the abluminal, extravascular space of single
pial microvessels in vivo produced a dose-dependent
increase of permeability to sulforhodamine B (580
Da). Intracarotid (i.e., luminal) bolus injection of PlGF-
1 or VEGF-E did not affect permeability.
(C) Flux measurements in primary brain MVECs
showed that pretreatment with 10 mM p38 inhibitor
SB202190 (SB) but not the PI3K inhibitor wortmannin
(WN) inhibited the permeability response to 50 ng/ml
VEGF-A.
(D) VEGF-A-induced permeability changes in pial
microvessels were abolished by pretreatment with
10 mM SB202190 but not wortmannin.
Shown are means ± SEM from at least three inde-
pendent experiments. *p < 0.05, **p < 0.01; ns, not
significant [Student’s t test (A), ANOVA and Dunnett’s
post hoc test (B and D), and two-way ANOVA and
Bonferroni’s post hoc test (C)].
See also Figure S4.
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in a 1:1 mixture of 2.3 M sucrose and 2% methylcellulose. The sections were
then stained as previously described (Slot et al., 1991) using antibodies against
VEGFR1 (sc-31173) (AF471; R&D Systems) and VEGFR2 (ab11939) (DC101).
Samples were viewed with a JEOL 1010 transmission electron microscope,
and images were gathered using a Gatan Orius SC100B charge-coupled de-
vice camera. Image manipulation was performed in Gatan Digital Micrograph
and Adobe Photoshop. VEGFR distribution was determined by visual inspec-
tion of electronmicrographs. Gold particles were considered luminal (apical) or
abluminal (basal) when found within 20 nm of the respective plasma mem-
brane (Ottersen, 1989).
Transendothelial Flux
Fluorescein isothiocyanate (FITC) dextran (4 kDa) flux across MVECs was
measured as previously described (Martins et al., 2013).
Transendothelial Electrical Resistance
TEER was measured directly with chopstick electrodes (Turowski et al.,
2004) and an EVOM voltohmmeter (World Precision Instruments). Alter-
natively, TEER was assessed by impedance spectroscopy using cells
grown either on 12 mm Transwells and a cellZscope (nanoAnalytics) or
on gold electrodes (eight-well 8W1E) and an ECIS (4,000 Hz) (Applied
BioPhysics).
Cytoprotection Assays
Caspase activity of MVECs grown in 96-well plates was measured using the
Apo-ONE Homogeneous Caspase-3/7 assay kit (Promega).
Cell-Surface Biotinylation
Apical and basal biotinylation was performed using a method adapted from
Gottardi et al. (1995). Basal biotinylation was very weak, presumably because
of reduced access through the filter and the basement membrane (Gottardi
et al., 1995). Therefore, apical and basal domains were labeled simultaneously
in the presence of EDTA. Biotinylated proteins were isolated on streptavidin
beads and, following immunoblotting for VEGF receptors, apical and basal sig-
nals were quantified by densitometry and normalized against input signals.
Basal signal was calculated from the combined apical and basal labeling
minus the apical signal.
Western Blots
For immunoblot analyses, samples were lysed in 50 mM Tris/Cl (pH 6.8),
2% SDS, 10% glycerol, 100 mM dithiothreitol (DTT), 100 nM calyculin A
(50 ml/cm2 of cells), separated by SDS-PAGE, electrotransferred to nitrocellu-
lose or polyvinylidene fluoride, and immunodecorated with phospho-specific
and total antibodies as previously described (Martinelli et al., 2009). Akt (phos-
pho-S473 and total), p38 (phospho-T180/Y182 and total), and anti-VEGFR2
antibodies were from Cell Signaling (55B11), and anti-VEGFR1 was from Ab-
cam (Y103).
VEGF Receptor Localization in Retinal and Pulmonary Vessels
Anti-VEGFR1 (sc-31173) and -VEGFR2 (DC101) antibodies (each at 6 mg/kg)
were injected into the left ventricle of anesthetized p20 mice (C57 BL/6J). After
5 min, the animals were perfused with PBS followed by 4% PFA. Retinae were
dissected out and processed for whole-mount staining (West et al., 2005). For
abluminal detection, dissected unfixed retinae of PBS-perfused mice were
overlaid with anti-VEGFR1 and -VEGFR2 antibodies (20 mg/ml) for 5 min,
washed three times briefly with PBS, and then fixed in 4% PFA for 1 hr. All
retinae were stained using anti-F4/80 (MCA497EL; AbD Serotec) and/or bio-
tinylated isolectin B4 (B1205; Vector Labs) and secondary antibodies to detect
bound VEGFR1 and -R2 antibodies.
Transversal (1 mm) sections of lungs from animals having undergone car-
diac injections were analyzed in a similar manner. All samples were analyzed
by confocal microscopy on a Zeiss LSM 700. Retinal flat mounts were imaged
with a pinhole aperture allowing capture of the entire primary plexus depth in a
single scan, whereas sections of lung were analyzed from projections of
sequential image stacks.
p38 and Akt Signaling In Vivo
For luminal stimulation, 120 mg/kg of VEGF-A, VEGF-E, or PlGF-1 or an equal
volume (100 ml) of saline was injected into the tail vein of anesthetized P23Wis-
tar rats. For abluminal stimulation, cranial windows were surgically introduced
and VEGFs were added at 100 ng/ml (final concentration) to the liquid pool
superfusing the pial microvasculature. Fiveminutes after injection/VEGF appli-
cation, animals were perfused and fixed and pial or lung sections were
processed for immunohistochemistry (Powner et al., 2010). For Akt analysis,
animals were injectedwith VEGFs in the tail vein as above or in the vitreous (us-
ing 100 ng of VEGF-A, VEGF-E, or PlGF-1 or an equal volume [5 ml] of saline).
After ca. 25 min, retinae were isolated and lysed in 50 mM Tris/Cl (pH 6.8), 2%
SDS, 10% glycerol, 100 mM DTT, 100 nM calyculin A and subjected to immu-
noblot analysis.
SUPPLEMENTAL INFORMATION
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Figure 6. VEGFR1 and Akt-Mediated Cyto-
protection in Brain Microvascular ECs
(A) Staurosporine (SSP; 1 mM, 60 min) more than
doubled caspase 3/7 activity in primary rat brain
MVECs when compared to untreated control cells
(NT). The staurosporine-induced caspase 3/7 ac-
tivity was significantly reduced by pretreatment
with VEGF-A and PlGF-1 but not VEGF-E (all at
50 ng/ml for 30 min).
(B) The VEGF-A-mediated reduction of staur-
osporine-induced caspase 3/7 activity was sensi-
tive to 10 mMPI3K inhibitor wortmannin but not the
p38 inhibitor SB202190.
Shown are means ± SEM (nR 15). ***p < 0.001; ns,
not significant (Student’s t test).
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